While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities across its footprint in the U.S., its largest market by revenue.

The planned investment makes London-based GSK the latest big pharmaceutical company to announce infrastructure plans in the U.S. amounting to billions or even tens of billions of dollars. GSK said its planned investments build on the company’s “strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States.”

Trump has repeatedly stated that big pharmaceutical companies should make more of their medicines in the U.S., and he has pu

See Full Page